论文部分内容阅读
目的:探讨雷珠单抗玻璃体内注射治疗早产儿视网膜病变的效果及对视网膜功能发育的影响。方法:抽取2017年5月至2020年7月于山西省儿童医院采用雷珠单抗玻璃体内注射治疗的视网膜病变早产儿39例为研究组，另抽取同期在兴安盟人民医院医院采用常规治疗的视网膜病变早产儿39例为参照组。回顾性比较两组治疗效果及患儿视网膜功能发育状况。结果:研究组病变控制率(92.61%，36/39)高于参照组(69.23%，27/39)，n P<0.05。研究组病变进展率(7.69%，3/39)、复发率(7.69%，3/39)低于参照组，n P<0.05。研究组视杆细胞系统反应振幅高于参照组、潜伏期短于参照组(n P<0.05)，研究组视锥细胞反应b波潜伏期短于参照组(n P<0.05)，研究组Ops高于参照组(n P<0.05)，研究组最大混合反应a、b波振幅高于参照组(n P<0.05)。研究组不良反应发生率为5.13%(2/39),低于参照组的66.67%(26/39)，n P<0.05。n 结论:对视网膜病变早产儿采用玻璃体内注射雷珠单抗能提高治疗效果，减少复发及不良反应，改善视网膜功能的发育。“,”Objective:To investigate the effect of intravitreal injection of ranibizumab on retinopathy of prematurity and its influence on development of retinal function.Methods:A total of 39 retinopathy of prematurity who were treated by intravitreal injection of ranibizumab in Shanxi Children’s Hospital from May 2017 to July 2020 were selected as the study group. Another 39 premature infants with retinopathy who received conventional treatment in Xing’an League People’s Hospital during the same period were selected as the reference group. The treatment effects and the development of child’s retinal function were retrospectively compared between the two groups.Results:The lesion control rate of the study group (92.61%, 36/39) was higher than that of the reference group (69.23%, 27/39), n P<0.05. The disease progression (7.69%, 3/39) and recurrence rate (7.69%, 3/39) of the study group were lower than those of the reference group,n P<0.05. The rod cell system response amplitude of the study group was higher than that of the reference group, and the apparent latency of the study group was shorter than that of the reference group (n P<0.05). The b-wave latency of cone response of the study group was shorter than that of the reference group (n P<0.05), the oscillatory potentials of the study group was higher than that of the reference group (n P<0.05), and the maximum mixed reaction a and b waves amplitude of the study group was higher than that of the reference group (n P<0.05).n Conclusions:Intravitreal injection of ranibizumab in retinopathy of prematurity can improve the therapeutic effect, reduce recurrence and adverse reactions, and improve the development of retinal function.